Skip to main content

Allogene Therapeutics, Inc. (ALLO)

NASDAQ: ALLO · IEX Real-Time Price · USD
18.91 0.16 (0.85%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap2.69B
Revenue (ttm)38.44M
Net Income (ttm)-250.71M
Shares Out142.52M
EPS (ttm)-1.88
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume655,968
Open18.55
Previous Close18.75
Day's Range17.86 - 19.11
52-Week Range12.90 - 39.12
Beta0.76
AnalystsBuy
Price Target35.19 (+86.1%)
Earnings DateNov 4, 2021

About ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin ...

IndustryBiotechnology
IPO DateOct 11, 2018
Employees301
Stock ExchangeNASDAQ
Ticker SymbolALLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is 35.19, which is an increase of 86.09% from the latest price.

Price Target
$35.19
(86.09% upside)
Analyst Consensus: Buy

News

Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2...

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

1 week ago - GlobeNewsWire

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

3 weeks ago - GlobeNewsWire

Allogene (ALLO) Misses on Q3 Earnings, Addresses Clinical Hold

Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.

1 month ago - Zacks Investment Research

Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

1 month ago - GlobeNewsWire

Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd An...

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

1 month ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allogene Therapeutics, Inc. - ALLO

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO).  Such investors are advis...

1 month ago - PRNewsWire

Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

1 month ago - GlobeNewsWire

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Other symbols:BEAMNTLA
1 month ago - The Motley Fool

Are Options Traders Betting on a Big Move in Allogene (ALLO) Stock?

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Allogene Therapeutics tanks 45% on Friday as FDA halts cancer drug trial

Shares of Allogene Therapeutics Inc (NASDAQ: ALLO) tanked 45% to $13.35 on Friday after the U.S. FDA put a hold on its Cancer drug trial. The sharp decline wiped millions off Allogene's market cap, leav...

2 months ago - Invezz

Why Allogene Therapeutics Stock Is Getting Hammered Today

A possible safety issue is crushing the biotech's shares today.

2 months ago - The Motley Fool

Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies

The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.

2 months ago - Zacks Investment Research

Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As Well

The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc (NASDAQ: ALLO) AlloCAR T trials in response to an abnormality t...

2 months ago - Benzinga

Should you buy or sell ALLO stock after shares plunge 37% as FDA halts clinical trial?

On Thursday, Allogene Therapeutics Inc. (NASDAQ:ALLO) shares plummeted by more than 37% in the after-hours session after the US Food and Drug Administration (FDA) put on hold the clinical trial for Allo...

2 months ago - Invezz

Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

2 months ago - GlobeNewsWire

Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

2 months ago - GlobeNewsWire

Allogene Therapeutics (ALLO) Up 9.6% Since Last Earnings Report: Can It Continue?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

3 months ago - GlobeNewsWire

Allogene's (ALLO) CAR T Therapy Gets Orphan Drug Status

Allogene's (ALLO) CAR T therapy, ALLO-715, gets orphan-drug designation in the United States. It is a potential treatment for multiple myeloma and other BCMA-positive malignancies.

3 months ago - Zacks Investment Research

Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma

The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc's (NASDAQ: ALLO) ALLO-715 to treat multiple myeloma. In April 2021, ALLO-715 received Regenerative Medicine Advanced Therapy (RMA...

3 months ago - Benzinga

Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...

3 months ago - GlobeNewsWire

Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances

Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.

4 months ago - Zacks Investment Research

Allogene Therapeutics Reports Second Quarter 2021 Financial Results

CD19 Program Highlights

4 months ago - GlobeNewsWire

Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

Collective Expertise in Strategic Development and Commercialization Will Guide Preparation of the Industry's First Potentially Pivotal Allogeneic CAR T Trial and Launch Collective Expertise in Strategic...

4 months ago - GlobeNewsWire

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

4 months ago - GlobeNewsWire